Company Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Delayed Nasdaq 04:00:00 2023-10-02 pm EDT Intraday chart for Gilead Sciences, Inc. 5-day change 1st Jan Change
74.10 USD -1.12% -0.98% -13.69%

Business Summary

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%) and other (37.2%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.3%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (70.6%), Europe (17.8%) and other (11.6%).

Number of employees : 17,000

Sales per Business

USD in Million2021Weight2022Weight Delta
Innovative Medicines
100.0 %
27,305 100.0 % 27,281 100.0 % -0.09%

Sales per region

USD in Million2021Weight2022Weight Delta
United States
69.2 %
19,267 70.6 % 18,884 69.2 % -1.99%
Europe
16.4 %
4,874 17.9 % 4,469 16.4 % -8.31%
Other International
14.4 %
3,164 11.6 % 3,928 14.4 % +24.15%

Managers

Managers TitleAgeSince
Chief Executive Officer 58 2019
Corporate Officer/Principal - -
Director of Finance/CFO 53 2019
Chief Tech/Sci/R&D Officer 60 2019
Chief Tech/Sci/R&D Officer - 2021
Investor Relations Contact - 2020
Corporate Officer/Principal - -
Corporate Officer/Principal - May. 29
Corporate Officer/Principal - -
Corporate Officer/Principal - 2022

Members of the board

Members of the board TitleAgeSince
Director/Board Member 52 2020
Chairman 58 2019
Director/Board Member 68 2009
Director/Board Member 68 2020
Director/Board Member 69 2018
Director/Board Member 55 2016
Director/Board Member 70 2017
Director/Board Member 74 2020
Director/Board Member 69 2020

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,246,014,353 1,244,667,375 ( 99.89 %) 0 99.89 %

Shareholders

NameEquities%Valuation
The Vanguard Group, Inc.
8.648 %
107,752,503 8.648 % 8 241 M $
Capital Research & Management Co. (World Investors)
6.620 %
82,483,680 6.620 % 6 308 M $
Capital Research & Management Co. (Global Investors)
3.365 %
41,930,321 3.365 % 3 207 M $
Dodge & Cox
2.207 %
27,504,392 2.207 % 2 104 M $
Geode Capital Management LLC
1.781 %
22,189,190 1.781 % 1 697 M $
Fidelity Management & Research Co. LLC
1.387 %
17,278,084 1.387 % 1 321 M $
Wellington Management Co. LLP
1.256 %
15,647,601 1.256 % 1 197 M $
Norges Bank Investment Management
1.043 %
12,989,938 1.043 % 993 M $
Capital International Ltd.
0.9585 %
11,943,115 0.9585 % 913 M $
Parnassus Investments LLC
0.8763 %
10,919,398 0.8763 % 835 M $
NameEquities%Valuation
Bram Bradesco Asset Management S/A DTVM
0.000330 %
8,220 0.000330 % 314 475 $
BB Gestão de Recursos DTVM SA
0.000276 %
6,886 0.000276 % 263 440 $

Holdings

NameEquities%Valuation
16,707,477 25.35% 634,671,106 $
14,823,029 19.90% 303,872,095 $
16,635,286 14.61% 52,068,445 $
3,478,261 7.19% 124,660,874 $
4,854,443 5.49% 31,505,335 $
3,759,465 4.61% 2,462,450 $

Company contact information

Gilead Sciences, Inc.

333 Lakeside Drive

94404, Foster City

+1 650 574 3000

http://www.gilead.com
address Gilead Sciences, Inc.(GILD)

Group companies

NameCategory and SectorSince
Gilead Sciences Ireland UC
-
2017
Gilead Therapeutics A1 Unlimited Co.
Health Technology - Pharmaceuticals: Major
2019
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer